Built on our proprietary ArtPure™ technology, Ternaria delivers the purity and performance modern therapeutics demand at every step of mRNA production. Through continuous innovation and uncompromising purity, we enable high-quality mRNA that performs consistently.
Deep tech
Who we are
Founded in 2021 in Reykjavík, Ternaria Biosciences develops enabling technologies that improve RNA-based therapeutics. Built on our ArtPure™ technology, our enzymes and mRNA solutions are engineered to deliver the accuracy, precision, and consistency that safe, effective RNA therapies demand — translating into fewer side effects and more predictable outcomes for patients.
We focus on the upstream technologies that shape every downstream result. By engineering higher-performing enzymes and optimized mRNA, we help researchers and developers improve yield, reproducibility, and scalability — whether in discovery, process development, or manufacturing.
Our customers span academia, biotechnology, pharmaceutical development, and manufacturing, united by one goal: delivering reproducible and accurate RNA function in cellular context.
Get in touchOur technology
ArtPure™ is Ternaria's proprietary technology platform — with the shared foundation of purity behind everything we build, from ultra-pure enzymes to novel enzyme discovery and cell-specific mRNA design.
01
Built around your needs
02
RNA enzymes & mRNA, in stock
Products
Ultra-pure RNA polymerases produced via ArtPure™ technology. Available in glycerol and lyophilized formats for flexible in vitro transcription workflows.
View products
Complete kits for reproducible in vitro transcription — optimised buffers, nucleotides, and ArtPure™ enzymes in a single workflow.
View products
Ready-to-use mRNA products and custom synthesis to your sequence, modification, and scale requirements — produced with ArtPure™ enzymes.
View productsOur Team
Professor of Cell Biology, University of Iceland. PhD from Oxford University. Research focus on autophagy and cancer. Former Chair of the Icelandic Research Council and Chair of the Icelandic Research Infrastructure fund.
PhD in Biochemistry from Medical College of Virginia. Postdoc at SUNY Stony Brook. 30+ years in protein chemistry and assay development across US institutes and corporations.
Professor of Molecular Biology, University of Iceland. PhD from UCLA, postdoc at NIH. Expert in gene transcription and melanoma. Former Chair of European Molecular Biology Labs (EMBL).
Extensive pharma and medtech leadership. Former C-level at Kerecis during its growth to unicorn. MSc Pharmacy + MBA.
PhD in cell biology from University of Glasgow and postdoctoral training University of Iceland. Various positions at University of Iceland and EMBL, Heidelberg. Shareholder and board member in a German family company.
Doctorate in drug delivery from the University of Iceland. Background in genetic engineering, enzymatic activity, and vaccine R&D.
PhD and postdoctoral training from Cornell University. Research focus on RNA biology and mRNA translation at untranslated regions. Functional genomics experience at Decode Genetics.
MSc in Molecular Life Sciences from the University of Iceland. Experience in biochemical techniques across diverse cell models.
MSc in Molecular Life Sciences from the University of Iceland. Experience in biochemical techniques including advanced microscopy.
Get in touch
Whether you have questions about our products, want to discuss a partnership, or are interested in Ternaria as an investor — we'd love to hear from you.
Send us a message